Haemaccel

Haemaccel is a solution for injection containing the colloid polygeline as the active ingredient. It is supplied in an unspecified strength as an intravenous fluid intended for volume expansion. The product is manufactured for the European market and is available by prescription only. Haemaccel works by providing oncotic pressure to increase intravascular plasma volume. It is used in settings to manage hypovolemia, shock, and fluid replacement during surgery or trauma.

Haemaccel is indicated for situations where rapid expansion of circulating blood volume is required.

- Treatment of hypovolemia due to blood loss, dehydration, or burns. - Management of circulatory shock in trauma or postoperative patients. - Fluid replacement during major surgery when blood loss is anticipated. - Support of intravascular volume in patients with sepsis or severe infection. - Adjunctive therapy for electrolyte-free volume expansion in pediatric or adult patients. - Temporary plasma volume expansion in patients awaiting definitive blood transfusion.

Adverse reactions to Haemaccel are generally related to its colloid nature and the intravenous route of administration. These events are typically mild and resolve without specific treatment, but clinicians monitor patients closely for any signs of worsening.

Common: - Mild fever or chills - Transient hypotension or hypertension - Nausea or vomiting - Local irritation at the injection site - Headache - Dizziness

Serious: - Anaphylactic or severe allergic reactions - Pulmonary edema due to fluid overload - Acute kidney injury in susceptible patients - Coagulopathy - Electrolyte imbalance

When using Haemaccel, clinicians should assess patient risk factors and monitor clinical parameters to minimize potential complications.

- Evaluate cardiac function before infusion in patients with heart failure. - Use caution in individuals with renal impairment or reduced urine output. - Avoid rapid large-volume administration in patients at risk of pulmonary edema. - Monitor blood pressure and central venous pressure during and after infusion. - Check for signs of allergic reaction, especially in patients with known colloid sensitivities. - Adjust dosage in pediatric patients based on weight and clinical response. - Discontinue infusion if severe hypotension or anaphylaxis occurs.

Haemaccel may interact with other intravenously administered agents, influencing fluid balance, coagulation, or cardiovascular stability.

Avoid: - Concurrent infusion of other synthetic colloids (e.g., hydroxyethyl starch) due to additive risk of renal dysfunction. - Simultaneous administration of high-dose vasopressors without volume assessment, which can exacerbate hypertension.

Use with caution: - Blood products such as packed red cells, as volume status should be balanced. - Diuretics, because they may alter the intended plasma expansion effect. - ACE inhibitors or ARBs, which can affect blood pressure response to volume loading. - Anticoagulants, since rapid plasma expansion may influence coagulation parameters.